Haven't given up on this price range. The date range though looks tough but solid info on the expansion trial presented at ASCO and the other various presentations happening in the next several weeks could still make it possible by mid June.
Sentiment: Strong Buy
tar, what I have learnt so far is that there are no real longs here. Most hold trading portions which they trade at 3 or above pulling it right back to 2.6 or lower. I can certainly do that but for some very strange reason I always hope that "it is this time" lol. The action that we are seeing now will catch a few hapless who buy in at 3+ while the traders push it up and sell. What I am thinking is if this company has anything good hopefully one day it will reward me but I hate to day trade and pay 30% to the fed. So I am a long (for good or bad I really dont know). Many you see here who are pumping now are just trading and will sell or have already sold. Let us hope CRIS eventually pulls out a big whopper both for us and the patients. good luck.
well said, the only thing that piqued my interest regarding the abstract conclusions was the claim 907 had shown clinical responses across multiple tumor types ("CUDC-907 has achieved objective responses and long-term SD across multiple tumor types and dosing schedules"). I thought the previous data had indicated CR in only the refractory/relapsed DLBCL tumor type. Just guessing. I too fear that in a couple weeks we will back to $2.30 if Curis indicates only that it is likely to initiate the phase two trial by the end of the year pending further data from expansion phase. I am staying positive, however, that just maybe something more definitive is coming.
there are pumpers here saying it will double at ASCO. We already seen the abstract. there is nothing new. Honest, rational positive posts from true longs are welcome but irrational pumping done by those who are shuttling back and forth between $2.6 and $3.15 is NASTY.
New commers please dont fall for this. I want CRIS to go to $5 but on true substantial news. Hate pumping because I know next week we will be back at 2.6 (95% chance based on past actions). I will still hold my 25K shares even though if I sell now I will take in significant profits.
SENTIMENT: Cautiously optimistic (dont jump in at the peak but watch how it plays).
Be real. On what basis?? you already saw the abstract didn't you? what more info are you expecting at the ASCO? I am ok with pumping but only by true longs. Those who are playing the ($2.6 to 3.15) shuttle are just that---pumpers.
I am a long and hold sizable position here. I know there are many day traders hopping in on the price action now. What is the possibility that we are being set up for another kill??
The good thing is I am not seeing a tremendous pump but still the uncertainty is huge with this one. The MMs will obviously try to fool all of us. I am sitting on significant profit now but again all of mine are long and it is always tempting to keep holding to shares that are long and have only a 15% tax on profits. Quite undecided today. What are longs up to?? target price?? Only rational honest answers please.
I believe I know what the MMs are doing. If you watch the small number of shares being offered at lower price than going rate to drive the price down yet later in the day small numbers are being bid for a fraction over the going asking price to slowly drive it back up. MMs appear to have two separate accounts to play this manipulating game back and forth.
ER was fine and ASCO will dramatically increase the PPS. CRIS is already a proven winner, chances are high under the FR Rule the company gets approval and you all get rich. Jus sayin...
Horrible ER / losing money when you have very little is never a good thing.....don't hold hope on possible drug approvals.....this company is burning through cash. Market will hammer CRIS today...
Sentiment: Strong Sell
in the upcoming weeks. Get ready.
-Sachs Immuno-Oncology: BD&L and Investment Forum in Chicago: May 29, 2015
-2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago: May 29-June 2, 2015
-Jefferies 2015 Global Healthcare Conference in New York City: June 1 - 4, 2015
-20th Congress of the European Hematology Association, Vienna. Austria; June 11 - 14, 2015
-2015 BIO International Convention in Philadelphia: June 15-18, 2015
-13th International Conference on Malignant Lymphoma, Lugano, Switzerland: June 17-20, 2015
Sentiment: Strong Buy
Below are conclusions taken from abstract, does not tell us anything we already know; have to wait and see what is said during poster presentation. Hopefully some light will be shed on expansion phases in which MTD was reached,
"Conclusions: The safety profile of CUDC-907 for gastrointestinal, hematologic, and hyperglycemic AEs was predictable based on experience with other HDAC and PI3K inhibitors. AEs have been reversible and managed with standard interventions or dose interruption, and fatigue and thrombocytopenia have not been dose limiting. CUDC-907 has achieved objective responses and long-term SD across multiple tumor types and dosing schedules, with objective response achieved in a heavily pretreated DLBCL patient population. Though MTD was not reached in the intermittent or 5/2 schedules, expansion is being studied at 120 mg TIW and 60 mg 5/2 dose levels based upon their efficacy and toxicity profiles. Clinical trial information: NCT01742"
Is CRIS on the right track? ExplosiveOTC is following their developments as well as a handful of other potential blockbusters. Find out what the next breakout stock will be and when you sign up you'll receive an incredible eBook about the market- just enter promo code CRIS .